Rupert Resources Reports NI 43-101 Inferred Resource for the Pahtavaara Project in Northern Finland
April 16, 2018 07:59 ET
|
Rupert Resources Ltd.
TORONTO, April 16, 2018 (GLOBE NEWSWIRE) -- Rupert Resources Ltd (“Rupert” or “the Company”) (TSX-V:RUP) (FSE:R05) announces a baseline resource for its Pahtavaara Project in the Central Lapland...
Molok scoops The New Economy’s Most Innovative Waste Management Company award
March 14, 2018 12:01 ET
|
The New Economy
LONDON, March 14, 2018 (GLOBE NEWSWIRE) -- For its exceptional work in waste management, Molok has won The New Economy magazine’s award for Most Innovative Waste Management Company. For years,...
Rupert Resources Recent Drilling at the Pahtavaara Project Indicating Extensions to Mineralisation and Base Metals Potential
March 01, 2018 08:00 ET
|
Rupert Resources Ltd.
TORONTO, March 01, 2018 (GLOBE NEWSWIRE) -- Rupert Resources Ltd (“Rupert” or the “Company”) (TSX VENTURE:RUP) (FRANKFURT:R05) provides an update on its activities at the Pahtavaara Project in the...
Molok scoops The New Economy’s Most Innovative Waste Management Company award 2017
February 14, 2018 03:30 ET
|
The New Economy
LONDON, Feb. 14, 2018 (GLOBE NEWSWIRE) -- For its exceptional work in waste management, Molok has won The New Economy magazine’s award for Most Innovative Waste Management Company 2017. For years,...
Molok’s scoops The New Economy’s Most Innovative Waste Management Company award 2017
January 25, 2018 07:10 ET
|
The New Economy
LONDON, Jan. 25, 2018 (GLOBE NEWSWIRE) -- For its exceptional work in waste management, Molok has won The New Economy magazine’s award for Most Innovative Waste Management Company 2017. For years,...
Laurantis Pharma and Ark Therapeutics Sign Manufacturing Agreement for Production of Lymfactin(TM) Investigational Treatment for Breast Cancer-Associated Lymphedema
October 15, 2012 08:00 ET
|
Laurantis Pharma Oy; Ark Therapeutics Group plc
LONDON and TURKU, FINLAND--(Marketwire - Oct 15, 2012) - Ark Therapeutics has been selected to manufacture and supply Lymfactin™ to Laurantis Pharma under a conditional agreement...
U.S. Patent Office Issues Patent to Laurantis for Cis-UCA as a Treatment for Bladder Cancer
October 09, 2012 08:00 ET
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Oct 9, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) for the use of cis-urocanic acid...
Laurantis Pharma Completes Funding Round for Research Program
September 04, 2012 07:59 ET
|
Laurantis Pharma OY
BOSTON, MA and TURKU, FINLAND--(Marketwire - Sep 4, 2012) - Laurantis Pharma today announced successful completion of a funding round, which raised EUR 5.64 million (US$7.02 million). A...
U.S. Patent Office Allows Laurantis Application for Treatment of Skin Inflammation
August 01, 2012 08:00 ET
|
Laurantis Pharma Oy
TURKU, FINLAND--(Marketwire - Aug 1, 2012) - The United States Patent and Trademark Office has allowed a patent application by Laurantis Pharma Oy (Laurantis) as it pertains to the topical...
Investigational Cis-urocanic Acid Eye Drops for Dry Eye Syndrome Well Tolerated, in Phase 1 Clinical Study
June 28, 2012 10:03 ET
|
Laurantis Pharma OY
TURKU, FINLAND--(Marketwire - Jun 28, 2012) - Laurantis Pharma today announced that it has completed a phase 1 clinical study with its Cis-urocanic acid eye drops. The objective of the study was to...